Acceleron Shares Open 50% Higher on Phase 2 PAH Trial Data

  ()
Acceleron Pharma's shares established a new 52-week high after the company reported that sotatercept achieved both primary and secondary endpoints in the Phase 2 PULSAR study in patients with pulmonary arterial hypertension. read more >

Inovio Pharma Awarded $9M Development Grant for Coronavirus Vaccine

  ()
Inovio Pharmaceuticals' shares rose 30%, setting a new 52-week high price, after the firm reported it received a grant of up to $9 million to develop a vaccine against the coronavirus. read more >

My Prediction for a Market Top in October Was Perhaps Left but Not Wrong

Contributed Opinion
  ()
Bob Moriarty of 321gold reflects on how government actions in the financial and public health spheres will pop market bubbles. read more >

eHealth Shares Rise 25% After Achieving 100% Increase in Quarterly Medicare Advantage Sales

  ()
Online medical exchange operator eHealth Inc.'s shares traded higher after the firm reported preliminary financial results for Q4/19 and FY/19. The company advised that both quarterly and annual revenues exceeded prior estimates. read more >

Premier Health Group Update: Charting 'Strongly Bullish' Movement

Contributed Opinion
  ()
Technical analyst Clive Maund examines this potential of the company's stock. read more >
News Update

Imaging System Developer Outlines Plan for 2020

News Update
  ()
The company continues to advance its device toward commercialization. read more >
News Update

Healthcare Tech Firm Now Has 90,000 Patients on Telemedicine Portal

News Update
  ()
The company continues to evolve this digital offering as well. read more >

Co-Diagnostics Utilizes CoPrimer Platform to Design New Coronavirus Detection Test

  ()
Molecular diagnostics company Co-Diagnostics' shares opened more than 144% higher after the firm reported it has designed a test for virus detection of the new coronavirus, 2019-nCoV, using its CoPrimerô platform. read more >

Neurotrope's Shares Double on Phase 2 Alzheimer's Study Data and $2.7 Million NIH Grant

  ()
Neurotrope's shares traded higher after reporting results from its Phase 2 "203" clinical trial of Byrostatin-1 for treatment of moderately severe to severe Alzheimer's patients. The firm was awarded a $2.7 million grant from the National Institutes of Health to conduct additional clinical research for patients with advanced Alzheimer's disease. read more >

Biopharma Shows 'Good Start to 2020 News Flow'

Research Report
  ()
The two developments that already took place this year are addressed in an H.C. Wainwright & Co. report. read more >

Expert Investing Ideas

"DRRX earned a $10M milestone payment from Gilead."

–Ed Arce, H.C. Wainwright & Co.


"The market for DRRX's POSIMIR could be substantial."

–Brian Marckx, Zacks Small-Cap Research


Learn More about Which Online Broker is Right for You?

Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe
NASDAQ Biotech ARCA Pharmaceutical

Genprex Shares Soar 250% on FDA Fast Track Designation for Lung Cancer Drug

  ()
Genprex's shares spiked 380% higher as the company reported that the FDA granted Fast Track Designation for its Oncoprex immunogene therapy in combination with EGFR inhibitor osimertinib. read more >

InMed Shares Trade Up 25% After Becoming First to Advance Cannabinol into Clinical Trials

  ()
InMed Pharmaceuticals shares traded 25% higher after reporting that it is the first to advance cannabinol into therapeutic clinical trials. read more >

NantKwest Shares Jump More than 50% Following JP Morgan Healthcare Conference Presentation

  ()
Shares of NantKwest Inc. spiked as much as 85% higher, setting a new 52-week high price, after the company reported a series of positive results at the 38th JP Morgan Healthcare Conference in San Francisco. The firm reported that complete responses were noted in as many as six different multiple tumor types when "natural killer" cells and T cells are activated simultaneously. read more >

Biotech Announces Deal with Bayer on Non-Hormonal Contraception

Research Report
  ()
Details of the arrangement and an update on the company's pipeline are provided in a Dawson James report. read more >